A Phase 1 Study of COTI-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies

Trial Profile

A Phase 1 Study of COTI-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs COTI 2 (Primary)
  • Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Head and neck cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Critical Outcome Technologies
  • Most Recent Events

    • 07 Feb 2017 Protocol amended with inclusion of head and neck cancer patients. Accordingly, patient number have been changed from 46 to 56 and inclusion criteria revised to include both male and female patients.
    • 07 Feb 2017 Planned end date changed from 1 Dec 2017 to 1 Dec 2018.
    • 07 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top